Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00323323 · ClinicalTrials.gov registry record · Phase 1
CHOP and Campath-1H in Previously Untreated Aggressive T/NK-Cell Lymphomas
A Phase 1 study, sponsored by Ohio State University Comprehensive Cancer Center.
- Completed
- Registry status
- Phase 1
- Development phase
- 24
- Enrollment target
NCT00323323 is a Phase 1 study that has completed, run by Ohio State University Comprehensive Cancer Center. The registered enrollment target is 24 participants.
The verdict
NCT00323323, a Phase 1 study, has completed, sponsored by Ohio State University Comprehensive Cancer Center.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 24 participants
- Enrollment target
Study Summary
Purpose: This study will evaluate the safety of CHOP plus Alemtuzumab in patients with T/NK cell lymphomas and CD-20 negative large B-cell lymphomas who have not had previous treatments. The biological response of lymphoma cells and the immune system to this drug combination will also be measured in patients before, during, and after therapy administration.
Interventions
- DRUG Alemtuzumab
- DRUG CHOP
- PROCEDURE Plasma Samples
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2004-03 |
| Est. Completion | 2016-10 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00323323
The ClinicalTrials.gov registry entry for NCT00323323 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 24 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Ohio State University Comprehensive Cancer Center, which has 341 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Alemtuzumab is the first listed.
NCT00323323 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00323323 about?
NCT00323323 is a clinical study titled "CHOP and Campath-1H in Previously Untreated Aggressive T/NK-Cell Lymphomas". Purpose: This study will evaluate the safety of CHOP plus Alemtuzumab in patients with T/NK cell lymphomas and CD-20 negative large B-cell lymphomas who have not had previous treatments. The biological response of lymphoma cells and the immune system to this drug combination will also be measured in...
What is the current status of trial NCT00323323?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 24 participants. The study started on 2004-03. Estimated completion is 2016-10.
What interventions are being tested in trial NCT00323323?
The interventions under investigation include: Alemtuzumab (DRUG), CHOP (DRUG), Plasma Samples (PROCEDURE).
Who is sponsoring clinical trial NCT00323323?
This trial is sponsored by Ohio State University Comprehensive Cancer Center, which has 341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.